Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astera Labs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astera Labs's regulatory disclosures and financial reporting.
ALAB filed a Form 144 notice reporting proposed sales of Common Stock by affiliated trusts through Morgan Stanley Smith Barney LLC. The notice lists multiple planned or completed 10b5-1 sales: 40,000 shares, 200,000 shares and repeat sales on 05/07/2026 and 05/19/2026. The filing identifies 400,000 shares associated with the seller entry and shows aggregate dollar amounts for individual trades in each row.
ALAB reported Form 144 activity disclosing sales of Common Stock by a related holder. The filing lists a 20,000 share lot described under the securities-to-be-sold section. It also records two recent transactions by TATE 1997 LIVING TRUST: 8,429 shares sold on 05/20/2026 for $2,290,075.01 and 49,665 shares sold on 05/14/2026 for $11,234,674.95.
Astera Labs, Inc. director and Chief Executive Officer Mohan Jitendra reported automatic sales of 95,444 shares of common stock. According to the disclosure, these shares were required to be sold to satisfy tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units and were executed under a pre‑elected "sell to cover" arrangement, not as discretionary trades.
Following these transactions, he continues to hold 1,357,295 shares of common stock directly, along with additional indirect holdings through several estate planning and living trusts.
Astera Labs, Inc. President and COO Gajendra Sanjay reported automatic tax-related share sales. On 2026-05-18, Form 4 shows the sale of 95,444 shares of Astera Labs common stock in multiple open-market transactions at prices between $216.10 and $235.94 per share.
According to a footnote, these sales were required to satisfy tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units and were executed under a pre-arranged “sell to cover” election, rather than as discretionary trades. Additional entries show large indirect holdings in three estate planning trusts, for which Sanjay disclaims beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara reported automatic sales of company stock tied to tax withholding. On May 18, 2026, he sold a total of 14,076 shares of Astera Labs common stock in open-market transactions.
According to the footnotes, these shares were required to be sold to satisfy tax withholding obligations from the vesting and settlement of previously granted restricted stock units. The company had elected in advance to use a “sell to cover” method, so the trades were automatic rather than discretionary. The shares were sold at weighted-average prices within ranges that span from about $216.10 to $235.94 per share.
Astera Labs, Inc. director and Chief Executive Officer Mohan Jitendra reported open‑market sales of 139,951 shares of Common Stock, carried out on behalf of a living trust. The sales occurred at weighted average prices within ranges between $210.0564 and $250.0100 per share.
The filing states these transactions were executed automatically under a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2025. The shares are held through a living trust and several estate planning trusts, for which the reporting person disclaims beneficial ownership except for any pecuniary interest.
ALAB submitted a Form 144 disclosing proposed and recent sales of Common Stock by a selling holder. The filing lists restricted stock vesting under a registered plan with vesting date 05/15/2025 in amounts 5,081, 1,502, and 1,846 shares. It also records a sale by TATE 1997 LIVING TRUST of 49,665 shares on 05/14/2026 for $11,234,674.95.
Form 144 notice: proposed sale of Common Stock. The filing lists a proposed sale of 40,000 shares with an associated value of $8,623,200.00 and a filing date of 05/19/2026. The excerpt also reports prior 10b5-1 sales on 05/07/2026 totaling 280,000 shares (examples: 40,000; 200,000; 40,000) with proceeds shown in the filing.
The notice identifies the securities as Common stock and records the original acquisition date as 11/21/2017 by private acquisition from the issuer or an affiliate. The excerpt lists trustee names and addresses associated with the prior 10b5-1 sales. This filing is a regulatory notice of a proposed sale; timing and cash-flow recipients are set by the selling holder information in the filing.
ALAB - Form 144 notice of proposed sale of restricted/common shares. The filing lists 40,000 shares of Common stock to be sold under Rule 144 with an aggregate dollar amount of $8,623,200.00. The filing notes prior 10b5-1 sales during the past three months totaling 280,000 shares across named trusts with aggregate proceeds recorded.
The securities to be sold were acquired 11/21/2017 (private acquisition from issuer or affiliate). The filing date shown is 05/19/2026 and sales listed as effected on 05/07/2026 for the prior transactions.
ALAB affiliate submits Form 144 to sell 200,000 shares. The filing lists 200,000 shares of Common stock associated with a sale and includes a $43,116,000.00 figure and an outstanding share count of 171,407,939 as shown in the excerpt.
The filing also records prior 10b5-1 sales on 05/07/2026 of 40,000, 200,000, and 40,000 Common shares with corresponding reported proceeds. The filing identifies the trades as connected to trusts and notes a Private Acquisition from Issuer or an Affiliate dated 11/21/2017.